In May 2026, Indonesia’s Ministry of Health issued and immediately enacted Ministerial Regulation No. 5 of 2026 on Health Supplies. This monumental policy is commonly referred to as Permenkes 5/2026.
This is arguably the most consequential piece of healthcare regulation Indonesia has issued in years, let alone this year.
In a single document, the Ministry has consolidated, streamlined, and significantly raised the bar for every entity involved in the Indonesian health supply chain. This impacts manufacturers, importers, distributors, wholesalers, retailers, and healthcare facilities alike.
The new health supplies regulation replaces 40 separate Ministerial Health Regulations that had accumulated since 1972. It effectively eliminates decades of overlapping and often contradictory rules with a single, coherent framework.
For companies operating in medical devices, pharmaceuticals, supplements, cosmetics, household health products (PKRT), and food for special medical purposes (PKMK), understanding this update is the new foundation of doing business. It is no longer optional.
Why Was This Regulation Necessary?
Indonesia’s Import Dependency Problem
The strategic necessity behind this framework is inseparable from a stark set of numbers. According to the Directorate General of Pharmaceuticals and Medical Devices (Ditjen Farmalkes), approximately 90% of Indonesia’s pharmaceutical raw materials are imported.
Furthermore, nearly 88% of its medical devices are still sourced from foreign markets. This severe dependency was thrown into sharp relief during the COVID-19 pandemic, when global supply chain disruptions left the country scrambling for critical health commodities.
The government’s medium-term development plan (RPJMN 2025–2029) places pharmaceutical and medical device self-sufficiency as a top national priority. This updated framework serves as the regulatory vehicle for achieving that ambition. It establishes firm rules of the road for a future in which Indonesia domestically produces more of what its healthcare system needs.
The Legislative Basis
This decree is issued as an implementing regulation for multiple articles of Government Regulation No. 28 of 2024. That regulation itself implements the landmark Health Law No. 17 of 2023.
This clear three-tier legislative chain—law, government regulation, and ministerial regulation—gives the framework firm constitutional grounding. It signals to international market participants that its provisions are intended to be durable and consistently enforced.
Consolidation of 40 Previous Regulations
One of the most immediately practical achievements of this text is its housekeeping role. It revokes and replaces 40 prior Ministerial Health Regulations spanning more than five decades.
These older documents ranged from Permenkes No. 167/1972 on retail drug traders to Permenkes No. 62/2017 on medical device marketing authorizations. For compliance teams managing multiple product categories, this consolidation is significant. There is now one primary document to read, interpret, and build corporate compliance programs around.
What Is Covered Under the Framework?
The regulation applies to the full lifecycle management of Perbekalan Kesehatan, which is a term best translated as health supplies. These are defined as all materials and equipment necessary to conduct health efforts.
In practice, this encompasses:
- Pharmaceutical products (obat, bahan obat)
- Medical devices (alat kesehatan), including in-vitro diagnostics (IVD)
- Household health products (Perbekalan Kesehatan Rumah Tangga / PKRT)
- Cosmetics (kosmetik)
- Health supplements (suplemen kesehatan)
- Traditional medicines (obat tradisional / bahan alam)
- Food for special medical purposes (Pangan untuk Keperluan Medis Khusus / PKMK)
The lifecycle stages covered include planning, production, procurement, distribution, price control, supervision, and post-market surveillance. In short, if your product or service touches any of these categories at any point in the Indonesian supply chain, these rules apply to you.
The Six Strategic Pillars of Permenkes 5/2026
1. Planning: A Demand-and-Supply Dual Approach
The regulation introduces a structured national planning framework for health supplies, built on two parallel tracks.
The first is a needs-based approach that generates the national health supply requirements plan. The second is a supply-based approach that maps production and import capacity against those requirements.
Central government, regional governments, and healthcare facilities are all mandated to prepare health supply needs plans. These are coordinated through government-owned pharmaceutical management facilities.
This moves Indonesia away from reactive, demand-pull procurement toward a more predictable, planned supply architecture.
In practice, manufacturers and importers operating at scale should expect growing engagement from government procurement bodies seeking alignment with national needs projections. Companies that can demonstrate alignment with government planning frameworks, especially for priority products, will have a clear commercial advantage.
2. Production Standards: CPB Certification Is Now Universal
Articles 13 and 15 establish that every health supply production facility must hold a valid business license and apply Good Manufacturing Practice (Cara Pembuatan yang Baik / CPB). Obtaining this specific CPB certification is now a universal mandate across all health supply categories.
Article 16 goes further, requiring each production facility to employ a dedicated, full-time responsible person with appropriate training credentials. For pharmaceutical manufacturers specifically, the regulation requires a minimum of four separate responsible persons.
Each must be dedicated to a distinct function: production, quality assurance, quality control, and distribution. This mirrors international GMP norms and signals an intent to align local manufacturing standards with global expectations.
Contract manufacturing (maklon) is also formally recognized. Article 18 explicitly permits production facilities to undertake contract manufacturing for third parties, provided all operations maintain a valid CPB certification.
This opens a legitimate and regulated pathway for foreign companies seeking local manufacturing partnerships without building their own facilities. This is a strategically important provision given the local content pressures described below.
There is also facilitation for small and micro enterprises. Article 21 carves out special accommodations for micro and small businesses (UMK) producing certain medical devices and PKRT. These businesses may use manual-to-semi-automated equipment and produce low-risk products under lighter-touch compliance conditions.
3. The TKDN Imperative: Local Content Is Now Formally Preferred
This is the provision with the most far-reaching commercial implications for international manufacturers and importers.
Article 41 mandates that government agencies and healthcare facilities must prioritize health supplies with the highest Local Content Certification (TKDN) value in all procurement decisions. Article 41(3) goes further, stating that products using domestic raw materials or components are permitted to carry a higher price than comparable imported products and still be preferred in government procurement.
Article 42 extends this preference explicitly to electronic catalogue (e-Katalog / LKPP) procurement. This formalizes what many in the industry have observed informally for years: a structural tilt in government procurement toward domestic production.
The key thresholds to understand are:
- Products exceeding 40% combined TKDN and BMP (Company Benefit Value) score receive absolute procurement preference in government facilities.
- TKDN alone must reach at least 25% to qualify for the relevant e-Katalog category.
- Products with TKDN above 52% unlock additional e-Katalog categories reserved for high-local-content products.
The regulation also obliges the government to mandate domestic raw material and component use in the production of fitofarmaka (standardized herbal medicines) and other designated health supply categories.
For international manufacturers, if your products are procured by Indonesian government hospitals, clinics, or health facilities, your TKDN score is now a competitive differentiator as significant as your price. Companies without a local manufacturing or contract manufacturing strategy should treat this provision as urgent.
4. Supply Chain Resilience: Buffer Stocks and Early Warning
Perhaps reflecting lessons from COVID-19 shortages, the framework introduces mandatory supply chain resilience requirements.
Article 40 outlines a strict buffer stock obligation. Production facilities, distributors, and pharmaceutical management facilities must calculate and maintain buffer stocks of between 10% and 30% of planned needs.
There is also an early warning reporting rule. Companies must report potential supply shortfalls to the government at least six months before the shortage is anticipated to occur.
This is a significant new obligation. Companies will need internal monitoring systems capable of providing this kind of advance visibility.
The regulation also requires a portion of production capacity to be reserved for emergency or crisis scenarios. This ensures that commercial production cycles do not crowd out emergency response capability.
Furthermore, all import activities must be processed through systems integrated with the Indonesia National Single Window (INSW). This includes imports of second-hand or refurbished medical devices and applications under the Special Access Scheme (SAS) for products not yet registered in Indonesia.
5. Distribution, E-Commerce, and Digital Integration
The decree formally legitimizes and regulates several modern distribution channels that have grown faster than the previous regulatory framework could accommodate.
Distribution through standalone retail drug stores (toko obat) is now formally regulated under this umbrella framework. Automated product dispensing machines or vending machines for health supplies are also explicitly addressed for the first time.
Online distribution through electronic trading systems (marketplaces or direct digital channels) is permitted, subject to integration with the National Health Information System (SIKN).
The regulation also mandates integration of electronic prescription services and electronic medical records within healthcare service distribution. This aligns with the broader SatuSehat national health digital infrastructure.
This digital integration requirement is non-trivial. Companies operating in e-commerce health product distribution will need to ensure their platforms are connected to government health information systems.
6. Price Transparency and Anti-Gratification Provisions
Meaningful new obligations around pricing transparency have been introduced.
Manufacturers, distributors, and healthcare facilities must report prices, discounts, and incentives directly to the central government. Pharmaceutical manufacturers are also required to print the Maximum Retail Price (Batasan Tertinggi Harga Jual) directly on product packaging.
Furthermore, the regulation explicitly prohibits gratification, such as kickbacks or improper incentives, in any health supply distribution activity.
These provisions signal a broader government intent to improve cost transparency across the health supply chain. This issue has historically complicated pricing negotiations in both public and private procurement.
Key Comparison: What Changed from Prior Regulations?
| 方面 | Under the New Framework | Under Prior Regulations |
| Regulatory architecture | Single unified regulation governing all health supply categories | 40+ separate sectoral regulations, often overlapping |
| Supply planning | Mandatory dual-track national planning (demand + supply approach) | Planning requirements scattered across sector-specific rules |
| GMP/GDP standards | Universal CPB and CDB mandatory for all facilities, evidenced by certificate | Production and distribution standards regulated separately per sector |
| TKDN preference | Formally mandated in government procurement; domestic products may price above imports | Preference existed in practice but lacked comprehensive regulatory basis |
| Buffer stock | Mandatory 10–30% of planned needs; production capacity reserves required | No unified buffer stock requirement across categories |
| Supply shortage reporting | 6-month advance early warning obligation | No standardized early warning timeline |
| E-commerce | Explicitly regulated, SIKN integration required | Addressed piecemeal or not at all |
| Price transparency | Mandatory price, discount, and incentive reporting; highest price on packaging | Incomplete transparency requirements across sectors |
| Sanctions | Tiered administrative sanctions including blacklisting and license revocation | Sanctions varied by sector and regulation |
Transition Period and Compliance Timeline
The Ministry of Health has provided two distinct transition windows:
- General provisions: A maximum 1-year transition period from the enactment date (4 May 2026), meaning most substantive compliance obligations must be met by 4 May 2027.
- Pharmaceutical import provisions: A 90-day transition period applies to certain pharmaceutical importation requirements, meaning these must be addressed by approximately early August 2026.
Companies should review which provisions apply to their operations and map internal compliance timelines against these deadlines. Given the breadth of the regulation, a phased compliance roadmap is advisable.
Sanctions for Non-Compliance
The text establishes a tiered administrative sanctions regime for violations:
- Written warning
- Administrative fine
- Temporary suspension of activities
- Product recall and destruction
- Electronic system blocking
- Blacklisting (daftar hitam)
- Business license revocation
The inclusion of blacklisting as a sanction is notable. It carries heavy reputational and commercial consequences beyond any single product or transaction. Companies should treat compliance not as a checkbox exercise but as a strict business continuity requirement.
Our Analysis: What This Means for Market Participants?
For International Medical Device Manufacturers
This framework makes explicit what Indonesian procurement policy has been quietly pursuing for years: a strong preference for locally manufactured or locally assembled products.
Combined with the existing TKDN e-catalogue requirements, the practical message for manufacturers without a local manufacturing presence is clear. A contract manufacturing (maklon) arrangement with an Indonesian partner holding a valid CPB certification is increasingly a necessary market access strategy.
The import integration with INSW and the six-month supply shortage reporting requirement will also demand more sophisticated supply chain monitoring and forecasting capabilities than many international companies currently have in place.
For Distributors and Importers
The unified CPB/CDB framework may prompt immediate compliance reviews and potentially CDAKB (Good Distribution Practice for Medical Devices) certification upgrades for distributors currently certified under older, sector-specific frameworks. The buffer stock obligation of 10–30% of planned needs also has direct working capital implications that should be factored into commercial planning.
For Pharmaceutical and Health Supplement Companies
The four-person responsible party requirement for pharmaceutical facilities and the universal CPB certification mandate raise the personnel and infrastructure bar for manufacturing.
Companies relying on contract manufacturing arrangements should verify their CMO partners’ status under the new framework. The maximum retail price labeling requirement will also require packaging updates within the transition period.
For Cosmetics and PKRT Producers
Cosmetics and household health products now fall explicitly under this unified framework, with CPB, CDB, and TKDN provisions applying alongside sector-specific BPOM regulations.
The combination of this text and the recently enacted PerBPOM No. 8/2026 (new cosmetics GMP certification) creates a layered compliance environment. This requires careful coordination between Kemenkes and BPOM compliance tracks.
A Regulatory Reset for Indonesia’s Health Supply Ecosystem
This updated decree represents a structural reset. It is an ambitious attempt to create a single, coherent regulatory architecture for all of Indonesia’s health supply management needs, driven by the twin imperatives of health system resilience and domestic industry development.
The regulation’s reach is broad. It touches manufacturers, importers, distributors, retailers, healthcare facilities, and digital health platforms simultaneously.
Its local content provisions formalize a procurement preference that will gradually but materially reshape market dynamics for international manufacturers. Its buffer stock and early warning requirements demand operational maturity in supply chain management.
Its digital integration provisions point toward a future in which health supply distribution is tracked and monitored in real time through national health information infrastructure.
For companies already established in the Indonesian health market, the new rules require a deliberate compliance review and a strategic rethink of market entry and supply chain architecture. For companies considering entering Indonesia, it defines the new baseline for what compliant operation looks like.
We recommend all companies affected by this regulation conduct a structured gap assessment against the new framework as a priority. It is wise to engage early with regulatory consultants and local partners to develop a realistic compliance roadmap before the transition windows close.
As your dedicated compliance partner, 印度尼西亚产品注册 provides the necessary legal scaffolding. We deliver the operational licenses, deep regulatory expertise, and compliance management needed to handle the market’s unique hurdles.
Partnering with Product Registration Indonesia allows global healthcare companies to focus entirely on brand building and commercial growth while ensuring absolute alignment with the newly enacted Permenkes 5/2026.
This article is prepared for informational and educational purposes by our regulatory intelligence team. It does not constitute legal or regulatory advice. Regulations are subject to implementing guidance and ministerial interpretation. We strongly recommend engaging qualified regulatory counsel for compliance decisions specific to your products and operations.
For consultation on compliance, TKDN strategy, certification, medical device registration, or market access planning in Indonesia, please contact our team.
